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Tobacco use remains the number one preventable cause of 
morbidity and mortality in Canada [1]. Based on the Canadian 
Tobacco Use Monitoring Survey (CTUMS), at present smoking rates 
for Canadians aged 15 years and older is 18%, representing about 
4.9 million smokers [2]. Although there has been a steady decline 
in the overall smoking prevalence in Canada during the last decade 
[3], some subsets of the population continue to smoke at high rates, 
particularly individuals with a history of substance use disorders 
(SUD) and/or psychiatric disorders (PD). Studies suggest that these 
individuals often have disproportionately higher mortality than the 
general U.S. population [4] - mortality which is often smoking related 
[5]. In the U.S., studies have estimated smoking rates of up to four 
times the national average among clinical populations with SUD 
and PD [6-8]. Although there are no estimates for smoking among 
individuals with PD in Canada as a whole, a recent survey among 
individuals with severe and persistent mental illness accessed through 
Community Mental Health Centres in Western Canada reported a 
smoking prevalence of 46.8% [9]. This high prevalence of smoking 
among individuals with SUD and PD clearly warrants a need for 
targetted efforts to reduce the disease burden and increased mortality 
risk among these often disparate sub-populations.
Fortunately, individuals with SUD and PD are often willing 
to engage in smoking cessation treatment with some measure of 
success. A survey among participants in a methadone maintenance 
treatment program found that 80% of smokers expressed an interest 
(i.e., responded: ‘somewhat’ or ‘very’ interested) in quitting smoking 
[10]. In a more recent review of nine studies assessing the motivation 
to quit smoking among individuals with PD, over 50% of smokers in 
this population contemplated quitting smoking in the next 60 days 
[11]. Moreover, previous studies have demonstrated that smoking 
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cessation interventions among individuals with co-occurring SUD’s 
may result in improved health outcomes [12] and drug abstinence [13-
16]. A meta-analysis of nineteen studies addressing smoking cessation 
interventions among individuals in addictions treatment and recovery 
found that such interventions resulted in increased smoking cessation 
at 12 week (although non-significant at 6-month follow-up) and a 25% 
likelihood of long-term abstinence from alcohol and illicit drugs [17]. 
These findings were corroborated by a recent review of the literature 
which found that smoking cessation interventions do not impair 
cessation from other substances of abuse and may actually enhance 
the success of substance abuse treatment [18]. Thus, with the current 
state of evidence, smoking cessation is not only contemplated but 
can result in improved health (and other substance abuse) outcomes 
among individuals with SUD and/or PD.
The purpose of this study is to report smoking cessation outcomes 
from a program with an innovative, tailored approach to smoking 
cessation among individuals with SUD and/or PD histories accessing 
outpatient addiction services [19]. Since its inception in September 
2007, the Tobacco Dependence Clinic (TDC) has provided services to 
over 700 tobacco dependent individuals with a history of SUD and/or 
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PD. The specific aims of this study are to examine:
a) Smoking cessation outcomes at end-of-treatment
b) Smoking cessation outcomes by histories of SUD, PD, or both
c) Predictors of successful smoking cessation
d) Predictors of successful program completion.
Methods
Setting and participants
The TDC provides smoking cessation treatment under the 
auspices of Vancouver Coastal Health (VCH) Mental Health and 
Addiction Services. Eligibility to participate in the TDC is based upon 
4 main criteria:1) 19 years or older, 2) tobacco dependent, 3) history 
of a substance use disorder and/or a mental illness, and 4) financially 
disadvantaged (i.e., individuals who had no source of income and/
or were on disability and/or demonstrated that their primary source 
of income is based on governmental assistance). Intake assessment 
includes obtaining of a medical, psychiatric, and previous tobacco 
use and treatment history, and vital signs and expired carbon 
monoxide (CO) monitoring. Participants also sign a consent form 
for information from their charts to be used for an ongoing program 
evaluation of the TDC. Currently, the TDC has seven operating sites 
at VCH Community Health Centres in Vancouver, BC.
Treatment approach and program completion
Current evidence-based guidelines recommend combining 
behavioural therapies with pharmacotherapy for optimal tobacco 
dependence treatment outcomes [20]. In keeping with these 
guidelines, the TDC program provides behavioural counselling 
with no-cost pharmacotherapy. The TDC program approach further 
assumes that smoking cessation is a process and not an event; as such, 
no set ‘quit date’ is emphasized in the program. Rather, behavioural 
counselling is provided during 8, weekly, “structured” group sessions 
of 1.5 hours duration followed immediately by a further optional 18, 
weekly, “support” group sessions of 1 hour duration. The behavioural 
counseling sessions aim to enhance motivation and self-efficacy to 
quit smoking as well as to foster skills for relapse prevention and 
maintaining abstinence. Group sessions are based on a manual that 
is standardized between clinics and facilitated by a drug and alcohol 
counselor (see supplemental materials). Non-attendance at group is 
followed up by a supportive telephone call by a nurse/counsellor. 
Moreover, the novelty of the TDC program approach to tobacco 
dependence treatment is that pharmacotherapy is tailored to the 
participants’ need in terms of dose, duration of treatment, and 
potentially combining multiple smoking cessation medications. 
Unlike many traditional smoking cessation programs which provide 
pharmacotherapy for durations of 8 to 12 weeks, the TDC program 
employs, the principle of “titrating to effect” in which participants 
are offered nicotine replacement therapy (i.e., nicotine patch, gum, 
lozenge, and inhaler) and/or oral medications (i.e., bupropion and 
varenicline) at higher doses and for longer durations (up to 26 weeks) 
to optimize participants efforts in smoking cessation. This approach to 
pharmacotherapy is in recognition that traditional smoking cessation 
programs often use conservative pharmacotherapy approaches which 
may, in effect, ‘under dose’ participants, particularly individuals with 
SUD and/or PD which smoke at higher rates and have higher nicotine 
dependence than the general population. The medications are 
dispensed weekly after each group session during a brief consultation 
with the TDC nurse or physician. Each visit is charted, including 
type of medication dispensed and expired CO monitoring (where 
appropriate). Program completers are defined as those who complete 
at least 6 weeks of the 8-week structured program (allowing for two 
missed sessions). Non-completers are those who engaged for less than 
6 weeks before disengaging or dropping out from the program. 
Measures
Baseline sociodemographic data included sex (male vs. female) 
and age (in years). In addition, a smoking history obtained at the 
participants’ initial visit to the program included age at smoking 
initiation, number of cigarettes smoked per day (cigs per day), and 
importance and confidence in quitting smoking (both on a scale of 0 
to 10) [21,22]. Moreover, information on substance use (categorized 
as: none, alcohol, opiates, cocaine, marijuana, methamphetamine 
and related drugs) and psychiatric disorder (categorized as: none, 
mood disorder, anxiety disorder, psychotic disorder) histories were 
obtained. The psychiatric disorder history was assessed primarily 
by patient history and review of current and/or past medications. 
Finally, data was obtained from participant charts on the type of 
pharmacotherapy received during treatment (i.e., monotherapy vs. 
combination therapy), Fagerstrom Test for Nicotine Dependence 
(FTND) scores at beginning of treatment [23,24], weekly expired 
carbon monoxide (CO) levels measured in parts per million (ppm) 
[25], and total number of weeks in treatment. 
Data analysis
Retrospective data from participants’ charts were extracted by 
two research assistants for those enrolled in the seven TDC sites from 
September 2007 to May 2011.The characteristics of the sample were 
described using frequencies and means (M) with standard deviations 
(SD). Differences between program completers and non-completers 
for all study variables were analyzed using chi-square (with degrees 
of freedom=DF) for categorical and ordered categorical variables and 
independent sample t-tests (with Levine’s test for equality of variance) 
for all continuous variables. Of the 739 individuals that engaged with 
the TDC in the specified time frame, 196 (26.5%) had 2 or less contacts 
with the program (including intake assessment and orientation to the 
program) and were deemed insufficiently engaged in the program. We 
compared baseline characteristics between those who remained in the 
program and those who had 2 or less contacts and found that there 
were no differences in the sex (χ2=0.07, DF=1, p=.785) or self-disclosed 
diagnosis of a psychiatric disorder (χ2=0.67, DF=3, p=.879); however, 
individuals who did not engage in the program were younger in age 
(45.1yrs vs. 48.0yrs, p=.003), had lower mean nicotine dependence 
scores (5.7 vs. 6.1, p=.040) and had on average lower expired CO 
levels at baseline (18.3ppm vs. 20.7ppm, p=.027). Furthermore, 3 
individuals described their gender as ‘other’ than male or female and 
where excluded from further analysis. Thus the analysis is based on 
540 individuals. 
The primary outcome measure was smoking status at end-of-
treatment. End-of-treatment was defined as completing the 8-week 
structured group and stopping treatment (in consultation and 
agreement with program providers) any time within the additional 
nine to eighteen weeks of support group therapy. Successful smoking 
cessation was defined using seven-day point-prevalence of smoking 
abstinence (i.e., not smoking in the past 7 days, based on participant 
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self-report with biochemical validation of expired CO≤8ppm when 
available). If an expired CO level was not recorded on the participant’s 
chart at the end-of-treatment, we used a next-observation-carried-
backward (NOCB) or last-observation-carried-forward (LOCF) 
method [26], from the weekly expired CO record, validated by 
participants self-report of no cigarette use in the preceding week to 
determine abstinence. If there was no record in the chart regarding 
smoking status or available expired CO, the participant was considered 
still smoking and a treatment failure (n=60). Counting such 
missing records as failures is an approach which will conservatively 
underestimate (but not inflate) the effects of the treatment. 
The secondary outcomes were to examine smoking cessation by 
SUD and PD history, by length of stay in the program, and to assess 
predictors of successful smoking cessation and program completion. 
We employed chi-square analyses to examine smoking cessation by 
histories of SUD, PD, and co-occurring disorders (i.e., none vs. SUD 
only vs. PD only vs. both SUD and PD) and by length of stay in the 
program. To assess predictors of smoking cessation and program 
completion, we employed a two-step model building procedure [27]. 
In the first step, crude odds ratios (reported in Odds Ratio=OR, 
and 95% Confidence Intervals=95%CI) were used to determine the 
associations between smoking cessation and all study variables. In 
the second step, only variables associated with smoking cessation 
(alpha ≤.10) were included in the final multivariate analyses using 
adjusted odds ratios. In assessing predictors of smoking cessation, the 
final logistic regression analysis was further stratified by gender to 
determine disaggregated differences in smoking cessation outcomes 
among women and men. The Hosmer-Lemeshow test was employed 
to assess global goodness-of-fit. For analyses, a p-value of .05 or lower 
was used to determine statistical significance. All analyses were 
performed using PASW statistics version 18.0. 
Total
(N = 540)
Completersb
(n = 406)
Non-completersc
(n = 134) Difference**
n % n % n % χ2 (df),  p
Gender 9.53 (1), .002
Female 210 38.9 173 42.6 37 27.6
Male 330 61.1 233 57.4 97 72.4
Primary Substance Use History 5.20 (5), .393
None 65 12.0 51 12.6 14 10.4
Alcohol 183 33.9 129 31.8 54 40.3
Opiates* 64 11.9 51 12.6 13 9.7
Cocaine 140 25.9 105 25.9 35 26.1
Marijuana 63 11.7 52 12.8 11 8.2
Methamphetamine and related drugs 25 4.6 18 4.4 7 5.2
Primary Mental Health Diagnosisa 3.36 (3), .339
None 125 23.1 88 21.7 37 27.6
Mood disorder 301 55.7 227 55.9 74 55.2
Anxiety disorder 77 14.3 63 15.5 14 10.4
Psychotic disorder 37 6.9 28 6.9 9 6.7
Pharmacotherapyd 1.45 (1), .228
Monotherapy 141 26.9 103 25.6 38 31.1
Combination therapy 383 73.1 300 74.4 84 68.9
Mean SD Mean SD Mean SD t (df), p
Age of participant (years) 48.1 11.0 48.3 11.0 47.4 10.9 .833 (536), .405
Age at smoking initiation 14.8 4.9 14.9 5.0 14.5 4.7 .739 (532), .460
Importance of quitting 9.0 1.3 9.0 1.3 9.0 1.4 .286 (520), .775
Confidence in quitting 7.3 2.2 7.3 2.3 7.4 2.1 .330 (515), .741
Cigarettes smoked per day 21.0 10.3 21.1 10.6 20.6 9.5 .469 (538), .639
FTNDf at baseline 6.1 2.1 6.1 2.1 6.1 2.0 .325 (532), .746
CO level at baseline 20.7 12.5 20.6 12.1 21.2 13.5 .482 (520), .630
a. The ‘mood disorder’ category includes primarily individuals with depression and bipolar disorder.  The ‘anxiety disorder’ category includes individuals primarily with 
generalized anxiety disorder, posttraumatic stress disorder, and panic disorders. The ‘psychotic disorder’ category includes individuals with a primary past history of schizo-
phrenia, schizoaffective disorder, psychotic disorder. 
b. Program completers are individuals who had at least 6 contacts with the Tobacco Dependence Clinic program. The typical program involves 8 weeks (8 contact points) of 
a closed group therapy session. Individuals could miss no more than two weeks (two contacts) to still have meaningful participation in the program. Of program completers, 
8.4% (n =17) had 6 or 7 contacts with the program. 
c. Program non-completers are individuals who had engaged in the program for more than two weeks, but had a total of less than 6 contact points (i.e., less than 6 weeks 
in the program). 
d. Pharmacotherapy represents the form of treatment (i.e., monotherapy vs. combination therapy) in the first month of treatment.
e. mean differences between completers and non-completers is expected as, by definition, non-completers did not have more than 6 weeks (6 contacts) with the program. 
f.  FTND = Fagerstrom Test for Nicotine Dependence. This is a six-item questionnaire of nicotine dependence, scored on a scale of ‘0’ (low) and ‘10’ (high).
* opiates (i.e., oxycontin, codeine, methadone, heroin) 
** differences between groups was based on chi-square analysis for categorical variables and independent sample t-tests for continuous variables. 
Table 1: Sample Characteristics.
Citation:  Khara M, Okoli CTC (2011) Smoking Cessation Outcomes among Individuals with Substance Use and/or Psychiatric Disorders. J Addict 
Res Ther 2:115. doi:10.4172/2155-6105.1000115
Page 4 of 6
Volume 2 • Issue 4 • 1000115
J Addict Res Ther
ISSN:2155-6105 JART an open access journal 
Results
Sample characteristics
The participants were mostly male (61.1%) with a mean age of 48.1 
(SD=11.0) years. The most prevalent SUD and PD were alcohol use 
disorders (33.9%) and mood disorders (55.7%), respectively, and 68% 
of the sample had co-occurring SUD and PD. Approximately 75.2% of 
participants completed the program, with significantly more females 
completing the program compared to males. On average, program 
completers (n=406) attended the TDC for 14.6 weeks (SD=6.8) 
whereas non-completers (n=134) attended for 4 weeks (SD=0.8). There 
were no other differences in baseline characteristics between program 
completers and non-completers (Table 1). 
Smoking cessation at end-of-treatment
Among program completers, 41.1% (167/406) achieved abstinence 
by end-of-treatment. There was a significant likelihood of smoking 
cessation with increased length of stay in treatment (χ2=26.2, 
DF=4, p< .0001, see figure 1). A greater proportion of men achieve 
smoking cessation as compared to women (42.1% vs. 39.9%) albeit this 
difference was non-significant (p = .660).
Smoking cessation by history of SUD and/or PD
There were no significant differences in smoking cessation 
between different diagnostic groups for those with histories of a SUD 
(χ2=3.44, DF=5, p=.633) or a PD (χ2=3.88, DF=3, p=.274, see figure 2). 
When the participants were categorized by history of co-occurring 
psychiatric and substance use disorder, we found these individuals 
were less likely to achieve smoking cessation than those with no 
disorder, a SUD only, or a PD only (no disorder=43.8% vs. SUD 
only=46.7% vs. PD only=45.7% vs. co-occurring=38.9%), however, 
the differences between groups were non-significant.
Predictors of smoking cessation
Among the total sample of program completers, in the unadjusted 
logistic regression analyses of the first-step in the model building 
process, psychiatric disorder history (particularly anxiety disorder), 
use of monotherapy in the first 4 weeks of treatment, lower nicotine 
dependence scores, lower expired CO levels at baseline, and higher 
total number of visits to the TDC were associated with smoking 
cessation at alpha ≤ 1.0. However, in the adjusted multivariate analyses, 
having an anxiety disorder (as compared to no psychiatric disorder) 
lower FTND scores and expired CO levels at baseline, and having 
longer treatment duration were significant predictors of smoking 
cessation at the end-of-treatment (Table 2). However, when the data 
was disaggregated by sex, in the adjusted multivariate analysis among 
both women and men only having lower CO levels at baseline and 
longer treatment duration significantly predicted smoking cessation 
at the end-of-treatment. 
Predictors of successful program completion
In the first-step of the model building process, being female 
(OR=1.95, 95%CI=1.27-2.98) and having an anxiety disorder (relative 
to no psychiatric disorder) (OR=1.03, 95%CI=1.00-1.05) remained 
predictive of program completion at alpha < 1.0. However in the 
adjusted model only being female remained predictive of program 
completion. [n=540, Hosmer-Lemeshow goodness-of-fit: χ2=2.87 
(DF=4), p=.579]. 
Conclusions
This study presents the smoking cessation and program 
completion outcomes of individuals with a history of SUD and/or 
PD in an outpatient treatment setting. Moreover, these findings are 
an update of the findings from a pilot study of outcomes from the 
TDC [19]. Similar to the earlier pilot study, end-of-treatment smoking 
cessation outcomes were 41.1% among program completers. These 
end-of-treatment findings are comparable to those reported by 
similar tailored approaches to smoking cessation among individuals 
with SUD and/or PD. For example, among 231 male cigarette smokers 
enrolled in a Veterans Affairs Mental Health Clinic Smoking Cessation 
Program, Gershon Grand et al. [28] reported end-of-treatment 
outcomes of 36.4%. Also, in a recent examination of a tailored 
smoking cessation program among individuals with psychiatric 
disorders, Selby et al. [26] reported seven-day point-prevalence quit 
rates of 20.6% at end-of-treatment. Moreover, the pooled results of 
18 studies of smoking cessation interventions among individuals in 
addictions treatment and recovery reported smoking cessation rates 
of 20.5% among participants in the treatment groups vs. 8.6% among 
participants in the control groups at end-of-treatment (RR = 1.82, 95% 
CI = 1.45-2.29); [17] however, these studies did not specifically provide 
tailored smoking cessation interventions. 
In our current study, although individuals with histories of alcohol, 
opiates, and/or marijuana use and a history of co-occurring SUD and 
PD were less likely to achieve smoking cessation compared to those 
without such histories, the difference was not statistically significant. 
In a pilot study we had found that individuals with alcohol, opiate 
9-12 wks          13-16 wks       17-20 wks         21-26 wks
Figure 1: Smoking cessation by length of time in the program among program 
completers (n = 406, χ2 = 26.2, df = 4, p < .0001).
Figure 2: End-of-treatment smoking cessation rates by psychiatric disorder 
and substance use history among program completers (n = 406).
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and marijuana use were significantly less likely to achieve cessation 
as compared to those without an SUD [19]. The non-significant 
findings in our current study may be a reflection of the more rigorous 
tailoring of medications, in terms of using combination therapy with 
participants of the TDC. At least in theory, tailored approaches, when 
appropriately delivered should not produce differences in outcomes 
between diagnostic groups as has been observed in a previous study 
[26]. However, our assumptions can only be speculative at best given 
the observational nature of our current study. 
However, we found that lower expired CO levels at baseline 
and a longer duration of treatment remained significant predictors 
of successful smoking cessation. This finding is also supported by 
previous studies using such tailored approaches [26]. Moreover, our 
present findings further suggest that, on average, the benefit of length 
of treatment peaks at between 4 to 5 months (i.e., 16 to 20 weeks) 
duration. Therefore, when considering the optimal duration of tailored 
smoking cessation programming among individuals with SUD and/
or PD, our findings would suggest longer-term pharmacotherapy 
and counselling support beyond the traditional 8-12 week treatment 
models. 
In addition, we found that although there are no significant 
differences between men and women in terms of smoking cessation 
outcomes, women are twice as likely to complete the program when 
compared to men. Few studies have examined gender differences in 
program completion for smoking cessation programs in addictions 
treatment settings. A previous study found sex-disaggregated 
differences in predictors of program completion among men and 
women in a Health Management Organization (HMO) -based 
substance abuse program [29]. In the study, predictors of program 
completion among women included higher income and legal/agency 
referral, whereas older age predicted completion among men [29]. 
Although our current study did not obtain demographic measures 
other than sex and age of participants, we did find that older age was a 
predictor of program completion, and specifically among men. 
We had anticipated that using combinations of pharmacotherapy 
would have been an important significant predictor of abstinence 
due to recent evidence-based recommendations [30]. Surprisingly, 
when we compared those who were given some form of combination 
therapy (i.e., combination NRT and/or NRT with oral medications) 
with those who were given only a monotherapy (i.e., either a single 
NRT product or a single oral medication), we found that those 
given the combination therapy were less likely to achieve cessation 
compared to those given monotherapy, albeit, the difference was 
not significant in the multivariate analysis. As this study is not a 
controlled trial, it is challenging to know the reasons why we obtained 
such findings. However, future controlled trials may be required to 
assess the effectiveness of combination therapy over monotherapy 
among individuals with SUD and/or PD. 
One limitation of this study relates to the verification of smoking 
abstinence based on expired CO monitoring. Counted as treatment 
failures were 11% (i.e. 60/540) of participants without available expired 
CO levels at the end-of-treatment. Hence, the smoking cessation rates 
at end-of-treatment may be an underestimate. A second limitation is 
the retrospective design of the study which may introduce incomplete 
study groups and interpretive bias during the chart review. Moreover, 
because it is an observational study, no random assignment of 
participants to treatment groups was performed. A third limitation 
is that due to the transient nature of the population accessing the 
TDC services, follow-up beyond end-of-treatment was challenging, 
although several attempts were made. Without such follow-up data, we 
cannot determine the long-term effectiveness of these tailored smoking 
cessation outcomes. A fourth limitation is that beyond gender and 
age, no other socio-demographic variables (i.e., income, education) 
were obtained from the participants. However, all participants had 
to meet the criteria of being financially disadvantaged in order to 
Total Sampled Womend Mend
Odds Ratio 95%CI Odds Ratio 95%CI Odds Ratio 95%CI
Primary Mental Health Diagnosisa
None (reference) 1.00 - 1.00 - 1.00 -
Mood disorder .78 .45-1.35 1.75 .61-5.03 .54 .27-1.07
Anxiety disorder .45* .22-.94 .86 .25-2.93 .37 .13-1.05
Psychotic disorder .89 .35-2.25 2.54 .56-11.60 .62 .17-2.25
Pharmacotherapy 
Monotherapy 1.00 - - - - -
Combination Therapy .66 .40-.109 - - - -
Confidence in quitting - - - - 1.13 .99-1.29
FTNDc at baseline .88* .70-1.00 - - .93 .80-1.09
COc level at baseline (ppm) .98** .96-1.00 .97* .94-1.00 .97* .94-1.00
Total number of visitsc to the TDC 1.09*** 1.05-1.12 1.07** 1.02-1.13 1.08*** 1.04-1.13
aThe ‘mood disorder’ category includes primarily individuals with depression and bipolar disorder.  The ‘anxiety disorder’ category includes individuals primarily with general-
ized anxiety disorder, posttraumatic stress disorder, and panic disorders. The ‘psychotic disorder’ category includes individuals with a primary past history of schizophrenia, 
schizoaffective disorder, psychotic disorder.
bProgram completers are individuals who had at least 6 contacts with the Tobacco Dependence Clinic program. The typical program involves 8 weeks (8 contact points) of 
a closed group therapy session. Individuals could miss no more than two weeks (two contacts) to still have meaningful participation in the program. 
cFTND = Fagerstrom Test for Nicotine Dependence. This is a six-item questionnaire of nicotine dependence, scored on a scale of ‘0’ (low) and ‘10’ (high). CO = Expired 
Carbon monoxide. This is measured in parts per millimeter (ppm). 
For FTND, CO level at baseline, and Total number of visits, the odds ratios represent the odds of smoking cessation per each unit increase in the variable.
dHosmer-Lemeshow goodness-of-fit results for Total sample (n= 388): χ2= 8.02 (DF=8),  p=.432; for Women (n = 167):  χ2= 7.30 (DF=8),  p=.505; and for Men (n = 218): 
χ2= 14.00 (DF=8),  p=.082
*p <.05, **= p<.01, *** = p <.001
Table 2: Adjusted predictors of smoking cessation for 26 weeks for program completersb by gender.
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participate in the TDC program. Despite the inherent limitations in 
the design of the study, we believe this study is an important addition 
to the literature examining the effectiveness of tailored approaches to 
smoking cessation among individuals with SUD and/or PD in real-
life treatment settings. 
In summary, the findings of our study provide some evidence 
to suggest that an intensive, tailored approach to smoking cessation 
among individuals with SUD and/or PD’s can yield modest end-of-
treatment quit rates. Such an approach can yield high retention rates 
among participants, partly because it reduces barriers to smoking 
cessation by providing pharmacotherapy and counselling services at 
no-cost. Future studies may determine the benefits of combination 
therapy over monotherapy in this population, in addition to 
determining the long-term effect of such interventions. Such studies 
will be important to provide practice and policy directions in terms 
of the provision of smoking cessation in addictions and mental health 
treatment settings.
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